Nyxoah (NYXH) Expected to Announce Earnings on Tuesday

Nyxoah (NASDAQ:NYXH) is expected to be issuing its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.54) per share and revenue of $7.0490 million for the quarter. Individuals may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:30 PM ET.

Nyxoah (NASDAQ:NYXH) last posted its quarterly earnings results on Saturday, February 14th. The company reported ($0.69) earnings per share for the quarter. The firm had revenue of $6.62 million during the quarter. Nyxoah had a negative net margin of 884.69% and a negative return on equity of 139.18%. On average, analysts expect Nyxoah to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Nyxoah Price Performance

Shares of NASDAQ NYXH opened at $3.26 on Monday. The company has a market capitalization of $126.36 million, a P/E ratio of -1.22 and a beta of 1.56. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.25 and a quick ratio of 1.16. The company has a 50 day simple moving average of $3.30 and a 200-day simple moving average of $4.32. Nyxoah has a 1 year low of $2.76 and a 1 year high of $8.64.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Weiss Ratings cut Nyxoah from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, April 22nd. Stifel Nicolaus decreased their price target on Nyxoah from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, April 10th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $11.00 price target on shares of Nyxoah in a report on Monday, March 23rd. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.33.

Institutional Trading of Nyxoah

Institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE lifted its stake in Nyxoah by 72.4% during the second quarter. Bank of America Corp DE now owns 7,866 shares of the company’s stock worth $59,000 after purchasing an additional 3,303 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Nyxoah in the second quarter valued at $70,000. Citadel Advisors LLC purchased a new stake in shares of Nyxoah in the 3rd quarter valued at $98,000. Deutsche Bank AG lifted its stake in Nyxoah by 40.0% during the 4th quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock worth $161,000 after acquiring an additional 10,000 shares in the last quarter. Finally, Shay Capital LLC acquired a new position in Nyxoah during the 2nd quarter worth about $374,000.

About Nyxoah

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.